[1] C.L. Chaffer, R.A. Weinberg, A perspective on cancer cell metastasis, Science 331
(6024) (2011) 1559–1564.
[2] R.E. Coleman, A. Lipton, G.D. Roodman, T.A. Guise, B.F. Boyce, A.M. Brufsky,
P. Clezardin, P.I. Croucher, J.R. Gralow, P. Hadji, I. Holen, G.R. Mundy, M.
R. Smith, L.J. Suva, Metastasis and bone loss: advancing treatment and prevention,
Cancer Treat. Rev. 36 (8) (2010) 615–620.
[3] G.D. Roodman, Mechanisms of bone metastasis, N. Engl. J. Med. 350 (16) (2004)
1655–1664.
[4] L.S. Rosen, D.H. Gordon, W. Dugan Jr., P. Major, P.D. Eisenberg, L. Provencher,
M. Kaminski, J. Simeone, J. Seaman, B.L. Chen, R.E. Coleman, Zoledronic acid is
superior to pamidronate for the treatment of bone metastases in breast carcinoma
patients with at least one osteolytic lesion, Cancer 100 (1) (2004) 36–43.
[5] F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.
L. Chin, J.J. Vinholes, J.A. Goas, B. Chen, A randomized, placebo-controlled trial of
zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma,
J. Natl. Cancer Inst. 94 (19) (2002) 1458–1468.
[6] Z. Wang, D. Qiao, Y. Lu, D. Curtis, X. Wen, Y. Yao, H. Zhao, Systematic literature
review and network meta-analysis comparing bone-targeted agents for the
prevention of skeletal-related events in cancer patients with bone metastasis,
Oncologist 20 (4) (2015) 440–449.
[7] S.G. Ahn, S.H. Kim, H.M. Lee, S.A. Lee, J. Jeong, Survival benefit of zoledronic Acid
in postmenopausal breast cancer patients receiving aromatase inhibitors, J. Breast
Cancer 17 (4) (2014) 350–355.
[8] M. Martin, R. Bell, H. Bourgeois, A. Brufsky, I. Diel, A. Eniu, L. Fallowfield,
Y. Fujiwara, J. Jassem, A.H. Paterson, D. Ritchie, G.G. Steger, A. Stopeck, C. Vogel,
[27]
[28]
[29]
[30]
M. Fan, Q. Jiang, K. Chung, R. Dansey, A. Braun, Bone-related complications and
quality of life in advanced breast cancer: results from a randomized phase III trial
of denosumab versus zoledronic acid, Clin. Cancer Res. 18 (17) (2012) 4841–4849.
M.H. Wong, M.R. Stockler, N. Pavlakis, Bisphosphonates and other bone agents for
breast cancer, Cochrane Database Syst. Rev. 2 (2012) CD003474.
D.M. Black, R. Eastell, A.L. Adams, Atypical Femur Fracture Risk versus Fragility
Fracture Prevention with Bisphosphonates. Reply, N. Engl. J. Med. 383 (22) (2020)
2189–2190.
R.M. Dell, A.L. Adams, D.F. Greene, T.T. Funahashi, S.L. Silverman, E.O. Eisemon,
H. Zhou, R.J. Burchette, S.M. Ott, Incidence of atypical nontraumatic diaphyseal
fractures of the femur, J. Bone Miner. Res. 27 (12) (2012) 2544–2550.
L. Gani, N. Anthony, L. Dacay, P. Tan, L.R. Chong, T.F. King, Incidence of Atypical
Femoral Fracture and Its Mortality in a Single Center in Singapore, JBMR Plus 5 (8)
(2021) e10515.
B.A. Lenart, D.G. Lorich, J.M. Lane, Atypical fractures of the femoral diaphysis in
postmenopausal women taking alendronate, N. Engl. J. Med. 358 (12) (2008)
1304–1306.
J. Schilcher, K. Michaelsson, P. Aspenberg, Bisphosphonate use and atypical
fractures of the femoral shaft, N. Engl. J. Med. 364 (18) (2011) 1728–1737.
B.A. Lenart, A.S. Neviaser, S. Lyman, C.C. Chang, F. Edobor-Osula, B. Steele, M.
C. van der Meulen, D.G. Lorich, J.M. Lane, Association of low-energy femoral
fractures with prolonged bisphosphonate use: a case control study, Osteoporos Int.
20 (8) (2009) 1353–1362.
R.P. Meier, T.V. Perneger, R. Stern, R. Rizzoli, R.E. Peter, Increasing occurrence of
atypical femoral fractures associated with bisphosphonate use, Arch. Intern. Med.
172 (12) (2012) 930–936.
K.S. Khow, T.Y. Yong, Atypical femoral fracture in a patient treated with
denosumab, J. Bone Miner. Metab. 33 (3) (2015) 355–358.
M. Koizumi, T. Gokita, K. Toda, Impending Atypical Femoral Fracture in Patients
With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term
Bisphosphonate and Denosumab, Clin. Nucl. Med. 42 (6) (2017) 463–464.
R. Paparodis, B. Buehring, E.M. Pelley, N. Binkley, A case of an unusual
subtrochanteric fracture in a patient receiving denosumab, Endocr. Pract. 19 (3)
(2013) e64–e68.
R.N. Thompson, C.L. Armstrong, G. Heyburn, Bilateral atypical femoral fractures in
a patient prescribed denosumab - a case report, Bone 61 (2014) 44–47.
E. Shane, D. Burr, B. Abrahamsen, R.A. Adler, T.D. Brown, A.M. Cheung,
F. Cosman, J.R. Curtis, R. Dell, D.W. Dempster, P.R. Ebeling, T.A. Einhorn, H.
K. Genant, P. Geusens, K. Klaushofer, J.M. Lane, F. McKiernan, R. McKinney, A. Ng,
J. Nieves, R. O’Keefe, S. Papapoulos, T.S. Howe, M.C. van der Meulen, R.
S. Weinstein, M.P. Whyte, Atypical subtrochanteric and diaphyseal femoral
fractures: second report of a task force of the American Society for Bone and
Mineral Research, J. Bone Miner. Res. 29 (1) (2014) 1–23.
P.E. Shrout, J.L. Fleiss, Intraclass correlations: uses in assessing rater reliability,
Psychol. Bull. 86 (1979) 420–428, https://doi.org/10.1037//0033-2909.86.2.420.
S.T. Chang, A.S. Tenforde, C.D. Grimsrud, F.S. O’Ryan, J.R. Gonzalez, D.M. Baer,
M. Chandra, J.C. Lo, Atypical femur fractures among breast cancer and multiple
myeloma patients receiving intravenous bisphosphonate therapy, Bone 51 (3)
(2012) 524–527.
B.J. Edwards, M. Sun, D.P. West, M. Guindani, Y.H. Lin, H. Lu, M. Hu, C. Barcenas,
J. Bird, C. Feng, S. Saraykar, D. Tripathy, G.N. Hortobagyi, R. Gagel, W.
A. Murphy Jr., Incidence of Atypical Femur Fractures in Cancer Patients: The MD
Anderson Cancer Center Experience, J. Bone Miner. Res. 31 (8) (2016) 1569–1576.
M.E. Puhaindran, A. Farooki, M.R. Steensma, M. Hameed, J.H. Healey, P.J. Boland,
Atypical subtrochanteric femoral fractures in patients with skeletal malignant
involvement treated with intravenous bisphosphonates, J. Bone Joint Surg. Am. 93
(13) (2011) 1235–1242.
M. Takahashi, Y. Ozaki, R. Kizawa, J. Masuda, K. Sakamaki, K. Kinowaki,
T. Umezu, C. Kondoh, Y. Tanabe, N. Tamura, Y. Miura, T. Shigekawa, H. Kawabata,
N. Baba, H. Iguchi, T. Takano, Atypical femoral fracture in patients with bone
metastasis receiving denosumab therapy: a retrospective study and systematic
review, BMC Cancer 19 (1) (2019) 980.
S.P. Yang, T.W. Kim, P.J. Boland, A. Farooki, Retrospective Review of Atypical
Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab
Therapy, Oncologist 22 (4) (2017) 438–444.
H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings,
E. Czerwinski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster,
C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin,
N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment
in postmenopausal women with osteoporosis: results from the phase 3 randomised
FREEDOM trial and open-label extension, Lancet Diabetes Endocrinol. 5 (7) (2017)
513–523.
E. Shane, D. Burr, P.R. Ebeling, B. Abrahamsen, R.A. Adler, T.D. Brown, A.
M. Cheung, F. Cosman, J.R. Curtis, R. Dell, D. Dempster, T.A. Einhorn, H.
K. Genant, P. Geusens, K. Klaushofer, K. Koval, J.M. Lane, F. McKiernan,
R. McKinney, A. Ng, J. Nieves, R. O’Keefe, S. Papapoulos, H.T. Sen, M.C. van der
Meulen, R.S. Weinstein, M. Whyte, Atypical subtrochanteric and diaphyseal
femoral fractures: report of a task force of the American Society for Bone and
Mineral Research, J. Bone Miner. Res. 25 (11) (2010) 2267–2294.
D. Amadori, M. Aglietta, B. Alessi, L. Gianni, T. Ibrahim, G. Farina, F. Gaion,
F. Bertoldo, D. Santini, R. Rondena, P. Bogani, C.I. Ripamonti, Efficacy and safety
of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients
with bone metastases from breast cancer (ZOOM): a phase 3, open-label,
randomised, non-inferiority trial, Lancet Oncol. 14 (2013) 663–670, https://doi.
org/10.1016/S1470-2045(13)70174-8.
T. Fukui et al.
Journal of Bone Oncology 40 (2023) 100478
[31] M. Clemons, M. Ong, C. Stober, S. Ernst, C. Booth, C. Canil, M. Mates, A. Robinson,
P. Blanchette, A.A. Joy, J. Hilton, O. Aseyev, G. Pond, A. Jeong, B. Hutton,
S. Mazzarello, L. Vandermeer, I. Kushnir, D. Fergusson, REaCT investigators, A
randomised trial of 4- versus 12-weekly administration of bone-targeted agents in
patients with bone metastases from breast or castration-resistant prostate cancer,
Eur. J. Cancer 142 (2021) 132–140, https://doi.org/10.1016/j.ejca.2020.08.019.
[32] A.L. Himelstein, J.C. Foster, J.L. Khatcheressian, J.D. Roberts, D.K. Seisler, P.
J. Novotny, R. Qin, R.S. Go, S.S. Grubbs, T. O’Connor, M.R. Velasco Jr.,
D. Weckstein, A. O’Mara, C.L. Loprinzi, C.L. Shapiro, Effect of longer-interval vs
standard dosing of zoledronic acid on skeletal events in patients with bone
metastases: A randomized clinical trial, J. Am. Med. Assoc. 317 (2017) 48–58,
https://doi.org/10.1001/jama.2016.19425.
[33] G.N. Hortobagyi, C. Van Poznak, W.G. Harker, W.J. Gradishar, H. Chew, S.
R. Dakhil, B.B. Haley, N. Sauter, R. Mohanlal, M. Zheng, A. Lipton, Continued
treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with
breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial, JAMA
Oncol. 3 (2017) 906–912, https://doi.org/10.1001/jamaoncol.2016.6316.
[34] C.Y. Chiang, R.M. Zebaze, A. Ghasem-Zadeh, S. Iuliano-Burns, A. Hardidge,
E. Seeman, Teriparatide improves bone quality and healing of atypical femoral
fractures associated with bisphosphonate therapy, Bone 52 (1) (2013) 360–365.
[35] T.L. Lin, S.J. Wang, Y.C. Fong, C.J. Hsu, H.C. Hsu, C.H. Tsai, Discontinuation of
alendronate and administration of bone-forming agents after surgical nailing may
promote union of atypical femoral fractures in patients on long-term alendronate
therapy, BMC Res. Notes 6 (2013) 11.
[36] P. Aspenberg, H.K. Genant, T. Johansson, A.J. Nino, K. See, K. Krohn, P.A. GarcíaHern´
andez, C.P. Recknor, T.A. Einhorn, G.P. Dalsky, B.H. Mitlak, A. Fierlinger, M.
C. Lakshmanan, Teriparatide for acceleration of fracture repair in humans: a
prospective, randomized, double-blind study of 102 postmenopausal women with
[37]
[38]
[39]
[40]
[41]
[42]
distal radial fractures, J. Bone Miner. Res. 25 (2010) 404–414, https://doi.org/
10.1359/jbmr.090731.
S.J. Kim, H.S. Park, D.W. Lee, J.W. Lee, Short-term daily teriparatide improve
postoperative functional outcome and fracture healing in unstable
intertrochanteric fractures, Injury 50 (2019) 1364–1370, https://doi.org/10.1016/
j.injury.2019.06.002.
P. Peichl, L.A. Holzer, R. Maier, G. Holzer, Parathyroid hormone 1–84 accelerates
fracture-healing in pubic bones of elderly osteoporotic women, J. Bone Joint Surg.
Am. 93 (2011) 1583–1587, https://doi.org/10.2106/JBJS.J.01379.
B. Cadieux, R. Coleman, P. Jafarinasabian, A. Lipton, R.Z. Orlowski, F. Saad, G.
V. Scagliotti, K. Shimizu, A. Stopeck, Experience with denosumab (XGEVA(R)) for
prevention of skeletal-related events in the 10 years after approval, J. Bone Oncol.
33 (2022), 100416.
S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid,
P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta,
C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in
postmenopausal women with osteoporosis, N. Engl. J. Med. 361 (8) (2009)
756–765.
Y. Bogdan, P. Tornetta 3rd, T.A. Einhorn, P. Guy, L. Leveille, J. Robinson, M.
J. Bosse, N. Haines, D. Horwitz, C. Jones, E. Schemitsch, C. Sagi, B. Thomas,
D. Stahl, W. Ricci, M. Brady, D. Sanders, M. Kain, T.F. Higgins, C. Collinge,
S. Kottmeier, D. Friess, Healing Time and Complications in Operatively Treated
Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter
Retrospective Cohort, J. Orthop. Trauma 30 (4) (2016) 177–181.
A. Koh, E. Guerado, P.V. Giannoudis, Atypical femoral fractures related to
bisphosphonate treatment: issues and controversies related to their surgical
management, Bone Joint J 99-B (3) (2017) 295–302.
...
論文の公開元へ
